Contract development and manufacturing organizations (CDMOs) are focusing on providing more specialized services. That is one trend Ascendia CEO Jim Huang, PhD, discusses in a CDMO Special Feature published by Drug Development & Delivery.
Dr. Huang explains how Ascendia meets the criteria pharma companies now look for when partnering with a CDMO. Increasing API complexity, breadth and depth of formulation expertise in resolving compound physical-chemical and biopharmaceutical problems, and the ability to strengthen the intellectual property position of the client’s products are how pharma companies evaluate CDMOs. Ascendia excels in all these areas.
He also explained how Ascendia was awarded a lipid project transferred from a previous CDMO and within 3-4 months, Ascendia did more than resolve the stability issue that was a concern. Ascendia enabled room temperature storage instead of “store under refrigeration,” as well as resolved the formulation capsule’s incompatibility that was causing an extremely low yield.